Systemic lupus erythematosus presenting as pyoderma gangrenosum in two cases.
Masatlioğlu
Seval Pehlevan
SP
Department of Rheumatology, Haydarpaşa Numune Training and Research Hospital, Istanbul, Turkey. sevalmasatlioglu@yahoo.com
Göktay
Fatih
F
Mansur
Ayşe Tülin
AT
Akkaya
Ayşe Deniz
AD
Güneş
Pembegül
P
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000032:analysis / Q000097:blood; D017152:Antibodies, Antiphospholipid / Q000032:analysis / Q000097:blood; D017439:Cicatrix, Hypertrophic / Q000209:etiology; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000473:pathology* / Q000503:physiopathology; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D017511:Pyoderma Gangrenosum / Q000209:etiology* / Q000473:pathology* / Q000503:physiopathology; D012867:Skin / Q000276:immunology / Q000473:pathology / Q000503:physiopathology; D016896:Treatment Outcome; D014456:Ulcer / Q000209:etiology* / Q000473:pathology* / Q000503:physiopathology
D000893:Anti-Inflammatory Agents; D019268:Antibodies, Antineutrophil Cytoplasmic; D017152:Antibodies, Antiphospholipid; D006886:Hydroxychloroquine; D016572:Cyclosporine; D011239:Prednisolone